Clinical trial
A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With…
NCT03280537 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT03280537 |
|---|---|
| Title | A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps |
| Official title | A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Clinical Trial of Omalizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps |
| Acronym | POLYP 2 |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Nasal Polyps, Chronic Rhinosinusitis |
| Intervention type | Drug |
| Interventions | Omalizumab, Placebo |
| Enrollment | 127 |
| Start date | Nov 21, 2017 |
| Primary completion | Mar 7, 2019 |
| Completion | Mar 7, 2019 |
| First posted | Sep 12, 2017 |
| Last update posted | Mar 23, 2020 |
| Countries | Belgium, Finland, France, Hungary, Mexico, Poland, Russia, Spain, Ukraine, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: